[Treatment of two cases of extramedullary infiltration multiple myeloma with BCMA CAR-T cells]
- PMID: 33910313
- PMCID: PMC8081939
- DOI: 10.3760/cma.j.issn.0253-2727.2021.03.013
[Treatment of two cases of extramedullary infiltration multiple myeloma with BCMA CAR-T cells]
Similar articles
-
Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.Front Immunol. 2021 Aug 5;12:720571. doi: 10.3389/fimmu.2021.720571. eCollection 2021. Front Immunol. 2021. PMID: 34421924 Free PMC article.
-
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.J Clin Oncol. 2018 Aug 1;36(22):2267-2280. doi: 10.1200/JCO.2018.77.8084. Epub 2018 May 29. J Clin Oncol. 2018. PMID: 29812997 Free PMC article.
-
Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials.Front Immunol. 2021 Oct 29;12:755866. doi: 10.3389/fimmu.2021.755866. eCollection 2021. Front Immunol. 2021. PMID: 34777368 Free PMC article.
-
Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.Ann Hematol. 2019 Apr;98(4):813-822. doi: 10.1007/s00277-018-03592-9. Epub 2019 Jan 28. Ann Hematol. 2019. PMID: 30693373 Free PMC article. Review.
-
B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma: A meta-analysis.Eur J Haematol. 2020 Apr;104(4):318-327. doi: 10.1111/ejh.13380. Epub 2020 Jan 20. Eur J Haematol. 2020. PMID: 31883150 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials